糖化CD59是孕期糖尿病的潜在生物标志物
Wanying Wang1, Chong Xu1, Xiaofan Lu1
1Department of Endocrinology, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, Jiangsu, China.
Frontiers in endocrinology
|October 1, 2024
概括
糖化CD59 (gCD59) 是妊娠糖尿病 (GDM) 的独立风险因素. 升高的gCD59水平显示了GDM的诊断价值,特别是当与禁食葡萄糖水平相结合时.
科学领域:
- 内分泌学 在内分泌学.
- 生殖医学 生殖医学
- 生物化学 生物化学
背景情况:
- 孕期糖尿病 (GDM) 对母亲和胎儿的健康构成风险.
- 早期和准确的GDM诊断对于有效的管理至关重要.
- 对于GDM诊断的生物标志物需要进一步调查.
研究的目的:
- 评估糖化CD59 (gCD59) 在识别妊娠糖尿病 (GDM) 中的诊断效用.
- 确定gCD59是否作为GDM发展的独立风险因素.
主要方法:
- 酶相关免疫吸收试验 (ELISA) 用于测量707名孕妇的gCD59水平.
- 根据IADPSG标准,参与者被分为GDM和正常葡萄糖耐受 (NGT) 组.
- 使用多变量逻辑回归和ROC曲线分析来评估风险因素和诊断准确性.
主要成果:
- 与NGT组相比,GDM组的gCD59水平明显高于NGT组.
- 鉴定出gCD59,腹筋血压 (DBP) 和甲状腺刺激激素 (TSH) 是GDM的独立风险因素.
- gCD59的诊断AUC为0.681,在与禁食葡萄糖相结合时改善到0.871.
结论:
- 糖化CD59 (gCD59) 是妊娠糖尿病 (GDM) 的独立风险因素.
- gCD59显示出作为一种有价值的生物标志物用于诊断GDM的前景,特别是与禁食葡萄糖结合使用.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Pathophysiology of Diabetes
894
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
894
Diabetes: Symptoms, Diagnosis, and Complications
515
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
515
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Hypoglycemia and Glucagon
206
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
206
Glucagon-like Receptor Agonists
302
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
302


